A Revolution in Wearable Therapeutics

Restless Legs Syndrome (RLS) is a neurological disorder affects the ability to fall and stay asleep for more than 10% of the western adult population, making it the second most common sleep disorder in the world. In the United States alone, more than 25 million adults suffer with symptoms of RLS; 8M of whom have severe symptoms that prevent them from being able to fall asleep more than 3 nights each week. These sensations of RLS are most prevalent at night, thus leading to sleep deprivation and its downstream consequences of depressed mood, irritability, forgetfulness, difficulty learning, and lack of motivation. As such, patients with RLS suffer from all the same downstream risks caused by sleep deprivation including clinical depression – a recent study shows RLS patients were nearly three times more likely to inflict self-harm.

Our first product (NTX100) aims to treat symptoms of moderate-severe Restless Legs Syndrome (RLS) and has won a “Breakthrough Device Designation (BDD)” from the US FDA, a first-in-class for a non-invasive medical device.